“Gout Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gout Market.

The Gout Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Gout Pipeline Report:

• Companies across the globe are diligently working toward developing novel Gout treatment therapies with a considerable amount of success over the years.

• Gout companies working in the treatment market are TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC, Shanton Pharma Co., Ltd., LG Chem, and others, are developing therapies for the Gout treatment

• Emerging Gout therapies in the different phases of clinical trials are- TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, and others are expected to have a significant impact on the Gout market in the coming years.

• In March 2025, Arthrosi Therapeutics, Inc., a late-stage biotech company advancing a next-generation URAT1 inhibitor designed to significantly lower serum urate (sUA) levels, reduce gout flares, and dissolve tophi in patients with gout and tophaceous gout, has announced the first patient has been dosed in REDUCE 1, its second pivotal Phase 3 clinical trial assessing the investigational therapy AR882.

• In January 2025, XORTX Therapeutics announced the initiation of a new late-stage program, XRx-026, aimed at treating gout in individuals who cannot tolerate allopurinol.

• In December 2024, Arthrosi Therapeutics announced that over 50% of patients have been enrolled in its pivotal Phase III REDUCE 2 trial, assessing AR882 for lowering serum urate in gout patients.

• In June 2024, Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a highly potent and selective next-generation URAT1 inhibitor designed to lower serum urate levels, reduce flares, and address Tophi in gout patients, announced today the dosing of the first patient in REDUCE 2, a pivotal Phase 3 clinical trial aimed at assessing the reduction of sUA levels in individuals with gout.

• In February 2024, PK Med, a biotechnology company headquartered in France, has obtained clearance from the US Food and Drug Administration (FDA) to progress its injectable gout treatment, PKM-01, directly into Phase II clinical trials, bypassing Phase I studies. The Phase II trial will assess three different doses of PKM-01, a combination therapy consisting of controlled-release colchicine with ropivacaine, an anesthetic. This prospective, randomized study aims to determine the optimal dosage of the treatment for further advancement into Phase III trials.

Gout Overview

Gout is a type of inflammatory arthritis caused by the buildup of uric acid crystals in the joints. It typically affects the big toe, but can also occur in other joints like the ankles, knees, or wrists. Gout attacks come on suddenly and cause intense pain, swelling, redness, and warmth in the affected joint. High levels of uric acid in the blood—often due to diet, genetics, or kidney issues—trigger the condition. Treatment includes anti-inflammatory medications, uric acid-lowering drugs, and lifestyle changes such as reducing red meat, alcohol, and sugary drinks. Early treatment can help prevent recurrent attacks and joint damage.

Get a Free Sample PDF Report to know more about Gout Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight

Emerging Gout Drugs Under Different Phases of Clinical Development Include:

• TJC-0434: TaiwanJ Pharmaceuticals

• NC-2700: Nippon Chemiphar

• Research Program: HemoShear Horizon Therapeutics plc

• NC-2500: Nippon Chemiphar

• PRX-115: Protalix BioTherapeutics

• HZN-457: Horizon Therapeutics plc

• AR-882: Arthrosi Therapeutics

• DYV700: Dyve Biosciences

• LC350189: LG Chem

• SHR-4640: Jiangsu Hengrui Medicine Co.

• SEL-212: Selecta Biosciences Inc

• D-0120 + Allopurinol: InventisBio Co., Ltd

• ALLN-346: Allena Pharmaceuticals

• Dapansutrile: Olatec Therapeutics LLC

• SAP001: Shanton Pharma Co., Ltd.

• Tigulixostat: LG Chem

Gout Route of Administration

Gout pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intravenous

• Oral

• Parenteral

• Subcutaneous

• Topical

• Molecule Type

Gout Molecule Type

Gout Products have been categorized under various Molecule types, such as

• Protein

• Small interfering RNA

• Small molecule

• Product Type

Gout Pipeline Therapeutics Assessment

• Gout Assessment by Product Type

• Gout By Stage and Product Type

• Gout Assessment by Route of Administration

• Gout By Stage and Route of Administration

• Gout Assessment by Molecule Type

• Gout by Stage and Molecule Type

DelveInsight’s Gout Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Gout product details are provided in the report. Download the Gout pipeline report to learn more about the emerging Gout therapies

Some of the key companies in the Gout Therapeutics Market include:

Key companies developing therapies for Gout are – Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, Allena Pharmaceuticals, JW Pharmaceutical, Revive Therapeutics, Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Nippon Chemiphar, Sinovent, Shenyang Sunshine Pharmaceutical, Rigel Pharmaceuticals, Chongqing Fochon Pharmaceutical, Alnylam Pharmaceuticals, Enzychem Lifesciences, Arrowhead Pharmaceuticals, Horizon Therapeutics, and others.

Gout Pipeline Analysis:

The Gout pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Gout with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gout Treatment.

• Gout key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Gout Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gout market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gout drugs and therapies

Gout Pipeline Market Drivers

• The rise in the prevalence of Gout, Novel urate-lowering agents are some of the important factors that are fueling the Gout Market.

Gout Pipeline Market Barriers

• However, gaps in the quality of care, lack of knowledge about guidelines and evidence based gout management, lack of novel therapies in Gout pipeline and other factors are creating obstacles in the Gout Market growth.

Scope of Gout Pipeline Drug Insight

• Coverage: Global

• Key Gout Companies: TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC, Shanton Pharma Co., Ltd., LG Chem, and others

• Key Gout Therapies: TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, and others

• Gout Therapeutic Assessment: Gout current marketed and Gout emerging therapies

• Gout Market Dynamics: Gout market drivers and Gout market barriers

Request for Sample PDF Report for Gout Pipeline Assessment and clinical trials

Table of Contents

1. Gout Report Introduction

2. Gout Executive Summary

3. Gout Overview

4. Gout- Analytical Perspective In-depth Commercial Assessment

5. Gout Pipeline Therapeutics

6. Gout Late Stage Products (Phase II/III)

7. Gout Mid Stage Products (Phase II)

8. Gout Early Stage Products (Phase I)

9. Gout Preclinical Stage Products

10. Gout Therapeutics Assessment

11. Gout Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Gout Key Companies

14. Gout Key Products

15. Gout Unmet Needs

16 . Gout Market Drivers and Barriers

17. Gout Future Perspectives and Conclusion

18. Gout Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/